Korsan-Bengtsen K, Johsen M, Pehrsson N G
Thromb Haemost. 1977 Feb 28;37(1):98-103.
Comparisons between British Comparative Thromboplastic (BCT) and a factor II-VII-X determination method--Simplastic A--have been carried out monthly during the time from December 1973 to March 1976. On each occasion fresh plasma from 20 dicoumarol-treated patients was analyzed with the two methods. It was found that the linear regression model is well suited for the comparison, that the BCT thromboplastin did not change significantly during the study, and that the method of comparing has a coefficient of variation of approximately 6-8%. This means, for instance, that a ratio of 3.8 with BCT corresponds to a ratio of 3.5 +/- 0.26 with Simplastin A. Thus in one period you may have ratio 3 and in another ratio 4 as the lower limit of the therapeutic range although you use the same thromboplastin and the same method. The importance of having a stable reference thromboplastin and an established method of comparing thromboplastins is stressed.
在1973年12月至1976年3月期间，每月都对英国比较凝血活酶生成试验（BCT）和一种II - VII - X因子测定方法——简易凝血活酶生成试验A（Simplastic A）进行比较。每次都用这两种方法对20例接受双香豆素治疗患者的新鲜血浆进行分析。结果发现，线性回归模型非常适合这种比较，在研究期间BCT凝血活酶没有显著变化，且比较方法的变异系数约为6 - 8%。例如，这意味着BCT比值为3.8时，对应简易凝血活酶生成试验A（Simplastin A）的比值为3.5±0.26。因此，尽管使用的是相同的凝血活酶和相同的方法，但在一个时期治疗范围的下限可能是比值3，而在另一个时期可能是比值4。强调了拥有稳定的参比凝血活酶和既定的凝血活酶比较方法的重要性。
